Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

Study Overview

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Study Description

The purpose of this clinical research study is to find out if the drugs dabrafenib and trametinib are safe and beneficial in people with BRAF mutation positive LGG or relapsed or refractory BRAF mutation positive HGG.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1803872717 (PHO-FERG-NOVARTIS-36G2201)
  • Research Study Identifier: TX8998
  • Principal Investigator: Michael Ferguson, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176